Bio-Inspired Mamba for Antibody-Antigen Interaction Prediction.

Publication date: May 26, 2025

Antibody lead discovery, crucial for immunotherapy development, requires identifying candidates with potent binding affinities to target antigens. Recent advances in protein language models have opened promising avenues to tackle this challenge by predicting antibody-antigen interactions (AAIs). Despite their appeals, precisely detecting binding sites (i. e., paratopes and epitopes) within the complex landscape of long-sequence biomolecules remains challenging. Herein, we propose MambaAAI, a bio-inspired model built upon the Mamba architecture, designed to predict AAIs and identify binding sites through selective attention mechanisms. Technically, we employ ESM-2, a pre-trained protein language model to extract evolutionarily enriched representations from input antigen and antibody sequences, which are modeled as residue-level interaction matrixes. Subsequently, a dual-view Mamba encoder is devised to capture important binding patterns, by dynamically learning embeddings of interaction matrixes from both antibody and antigen perspectives. Finally, the learned embeddings are decoded using a multilayer perceptron to output interaction probabilities. MambaAAI provides a unique advantage, relative to prior techniques, in dynamically selecting bio-enhancing residue sites that contribute to AAI prediction. We evaluate MambaAAI on two large-scale antibody-antigen neutralization datasets, and in silico results demonstrate that our method marginally outperforms the state-of-the-art baselines in terms of prediction accuracy, while maintaining robust generalization to unseen antibodies and antigens. In further analysis of the selective attention mechanism, we found that MambaAAI successfully uncovers critical epitope and paratope regions in the SARS-CoV-2 antibody examples. It is believed that MambaAAI holds great potential to discover lead candidates targeting specific antigens at a lower burden.

Open Access PDF

Concepts Keywords
Antibody Antigen-Antibody Reactions
Architecture Antigens
Biomolecules Antigens
Challenging Binding Sites
Models Binding Sites, Antibody
COVID-19
deep learning
Epitopes
Epitopes
Humans
Protein Binding
protein language model
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus

Semantics

Type Source Name
disease IDO protein
disease IDO process
drug DRUGBANK Amino acids
disease IDO immunodeficiency
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Porphobilinogen
drug DRUGBANK Aspartame
drug DRUGBANK Coenzyme M
drug DRUGBANK L-Leucine
disease IDO quality
drug DRUGBANK Sulpiride
disease IDO history
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Troleandomycin
drug DRUGBANK Lauric Acid
drug DRUGBANK Human vaccinia virus immune globulin
disease MESH COVID-19

Original Article

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *